Quinolines as chemotherapeutic agents for leishmaniasis
Kristie A Reynolds1, Wendy A Loughlin, David J Young
1Eskitis Institute for Cell and Molecular Therapies, Nathan Campus, Griffith University, Brisbane, QLD, 4111, Australia.
Abstract:
The development of leishmanicidal quinolines and their in vitro (promastigote and amastigote) and, where applicable, in vivo activities are reviewed. This survey provides a direct comparison of bioactivity across different species(e.g. L. donovani, L. amazonensis, L. chagasi, L infantum), and in different animal models (e.g. L. donovani Balb/c mice and L. donovani infected hamsters). The progress of selected quinolines through pre-clinical development and phase I/II trials, and the lead quinoline drugs sitamaquinine and Imiquimod, are discussed in conjunction with delivery systems and combination therapies.
More Related Videos
Related Concept Videos
Anthelminthic Agents
Inhibitors of Bacterial DNA Synthesis


